Anebulo Pharmaceuticals, Inc.

NasdaqCM:ANEB Stock Report

Market Cap: US$47.7m

Anebulo Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Anebulo Pharmaceuticals has been growing earnings at an average annual rate of 29%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Key information

29.0%

Earnings growth rate

43.6%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equity-215.1%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Revenue & Expenses Breakdown

How Anebulo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ANEB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-854
31 Mar 240-954
31 Dec 230-1065
30 Sep 230-1266
30 Jun 230-1266
31 Mar 230-1265
31 Dec 220-1165
30 Sep 220-843
30 Jun 220-743
31 Mar 220-3434
31 Dec 210-4133
30 Sep 210-4023
30 Jun 210-3812

Quality Earnings: ANEB is currently unprofitable.

Growing Profit Margin: ANEB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ANEB is unprofitable, but has reduced losses over the past 5 years at a rate of 29% per year.

Accelerating Growth: Unable to compare ANEB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANEB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Return on Equity

High ROE: ANEB has a negative Return on Equity (-215.12%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies